As biologics have increasingly superseded small molecules in the biopharma industry’s pipeline, the mounting complexity behind the manufacturing of those products is putting production and launches under pressure. A recent report highlights that while the shift towards biologics promises innovative therapies, it also introduces significant manufacturing challenges that can delay market entry. The intricate nature of biologics, including their sensitivity to environmental conditions and the need for specialized facilities, complicates the production process.
This trend underscores a critical issue for regulatory, QA/QC, and CMC professionals: the need for robust quality assurance and efficient supply chain management. As companies strive to balance the demand for novel biologics with the realities of manufacturing constraints, the implications for sourcing strategies and portfolio management become increasingly pronounced. Stakeholders must adapt to these challenges to ensure timely and successful product launches in a competitive landscape.
Get started today with Solo access →
